Regular ArticleSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
References (17)
- et al.
IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030
Diabetes Res. Clin. Pract.
(2011) - et al.
Global estimates of the prevalence of diabetes for 2010 and 2030
Diabetes Res. Clin. Pract.
(2010) Renal glucose reabsorption inhibitors to treat diabetes
Trends Pharmacol. Sci.
(2011)- et al.
Circadian rhythms in systemic hemodynamics and renal function in healthy subjects and patients with nephrotic syndrome
Kidney Int.
(2001) - et al.
Diabetes prevalence and body mass index differ by ethnicity: the Multiethnic Cohort
Ethn. Dis.
(2009) - et al.
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Diabetologia
(2009) - et al.
Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?
BMJ
(2006) - et al.
Clinical practice in type 2 diabetes: After metformin and lifestyle, then what?
J. Fam. Pract.
(2009)
There are more references available in the full text version of this article.
Cited by (0)
The study was funded by Boehringer Ingelheim.
Copyright © 2013 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.